Literature DB >> 12707627

The natural history of thyroid autonomy and hot nodules.

B Corvilain1.   

Abstract

Solitary hyperfunctioning thyroid adenomas are benign monoclonal tumors characterized by their capacity to grow and produce thyroxine (T4) and triiodothyronine (T3) autonomously, i.e. in the absence of thyrotropin (TSH). Mutations of the TSH receptor (TSH-R) have been found in the majority of solitary hyperfunctioning thyroid adenomas. On radioisotope scanning they generally appear as hot nodules because they concentrate radioiodide or 99mTc pertechnate, whereas the normal surrounding and contralateral tissue concentrate little isotopes. A toxic adenoma probably evolves gradually from a small autonomously hyperfunctioning adenoma that initially is only slightly more active than the extranodular tissue. This has been referred to as a "warm" nodule or a "compensated" adenoma. The diagnostic criterion for this designation is the persistence of detectable serum TSH maintaining some radioiodine uptake by the extranodular tissue. This "compensated" adenoma persists as long as the autonomous hormone output is not sufficient to suppress thyrotropin, i.e. to cause hyperthyroidism. The rate of development of thyrotoxicosis in patients with hyperfunctioning adenomas who are euthyroid initially is about 4% per year and depends on the size of the adenoma, iodine intake and age of the patient. No clear relationship can be establish between the nature of the TSH receptor mutations and the phenotype of the tumor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707627

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  8 in total

1.  Heterogeneous malignancy in toxic thyroid nodules.

Authors:  L Foppiani; P Del Monte; A Marugo; A Arlandini; G Sartini; M Marugo; D Bernasconi
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

2.  Thyroid scintigraphy: an old tool is still the gold standard for an effective diagnosis of autonomously functioning thyroid nodules.

Authors:  F Ianni; G Perotti; A Prete; R M Paragliola; M P Ricciato; C Carrozza; M Salvatori; A Pontecorvi; S M Corsello
Journal:  J Endocrinol Invest       Date:  2012-06-25       Impact factor: 4.256

3.  Real-time elastography in autonomously functioning thyroid nodules: relationship with TSH levels, scintigraphy, and ultrasound patterns.

Authors:  Pierpaolo Trimboli; Gaetano Paone; Maria Chiara Zatelli; Luca Ceriani; Luca Giovanella
Journal:  Endocrine       Date:  2017-03-11       Impact factor: 3.633

4.  Higher TSH can be used as an additional risk factor in prediction of malignancy in euthyroid thyroid nodules evaluated by cytology based on Bethesda system.

Authors:  Husniye Baser; Oya Topaloglu; Abbas Ali Tam; Berna Evranos; Afra Alkan; Nuran Sungu; Ersin Gurkan Dumlu; Reyhan Ersoy; Bekir Cakir
Journal:  Endocrine       Date:  2016-03-14       Impact factor: 3.633

Review 5.  Is there still a role for thyroid scintigraphy in the workup of a thyroid nodule in the era of fine needle aspiration cytology and molecular testing?

Authors:  Rodrigo Moreno-Reyes; Aglaia Kyrilli; Maria Lytrivi; Carole Bourmorck; Rayan Chami; Bernard Corvilain
Journal:  F1000Res       Date:  2016-04-27

6.  Malignancy risk of hyperfunctioning thyroid nodules compared with non-toxic nodules: systematic review and a meta-analysis.

Authors:  Lorraine W Lau; Sana Ghaznavi; Alexandra D Frolkis; Alexandra Stephenson; Helen Lee Robertson; Doreen M Rabi; Ralf Paschke
Journal:  Thyroid Res       Date:  2021-02-25

Review 7.  Thyroid nodule management: clinical, ultrasound and cytopathological parameters for predicting malignancy.

Authors:  Frederico F R Maia; Denise Engelbrecht Zantut-Wittmann
Journal:  Clinics (Sao Paulo)       Date:  2012-08       Impact factor: 2.365

8.  Can Ultrasound Predict Malignancy in Patient with Thyroid Cold Nodule?

Authors:  Joko Wiyanto; Achmad Hussein Sundawa Kartamihardja; Trias Nugrahadi
Journal:  World J Nucl Med       Date:  2016-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.